Abstract:【Objective】 To demonstrate differences in osteogenic differentiation

we test the capacity of hMSC between the osteoporosis and the non-osteoporosis patients. 【Method】 Six cases of bone marrow derived from patients with lumbar operation

in which three patients were diagnosed with osteoporosis and three with non-osteoporosis. For each patient

hMSC were divided into control group and osteogenic induction group. hMSC were separated from fresh bone marrow by density centrifugation and expanded. Osteogenic differentiation of hMSC was induced by treatment with dexamethasone (100 nmoL/L)

ascorbic acid (0.05 mmoL/L)

β-glycerol phosphate (10 mmoL/L) and low glucose DMEM medium with 0.1 volume fraction fetal bovine serum. The hMSC proliferation was evaluated after the induction by simultaneous monitoring of CCK-8 value and alkaline phosphatase activity (ALP). RT-qPCR assay was used to identify the differentially expressed osteogenic gene Runx-2

ALP

osteocalcin (OC) and osteonectin (ON). The formation of mineralized nodule was verified by staining with Alizarin red S as well as calculated by calcium quantitative assay. 【Result】 The values of proliferation were in creased signicantly in non-osteoporosis group

while the ALP indices showed to significant differences between the groups. RT-qPCR assay indicated that

compared to osteoporosis group

Runx-2 and ALP were up-regulated on day 3 and 7

OC was up-regulated on day 3

7 and 14

ON was up-regulated on day 7. The calcium nodules staining and quantitative assay showed that the capacity of hMSC in osteoporosis group was suppressed during the process of osteogenic induction

in comparison to the non-osteoporosis group. 【Conclusion】 Our data suggest multipotency of hMSC were suppressed by osteoporosis in osteogenic differentiation

which is induced by dexamethasone

ascorbic acid

and β-glycerol phosphate. Hence

it may not suitable for applying hMSC from osteoporosis patient in treatiment of their own disease.